COVID-19 in multiple sclerosis and neuromyelitis optica spectrum disorder patients in Latin America
- 6 March 2021
- journal article
- research article
- Published by Elsevier BV in Multiple Sclerosis and Related Disorders
- Vol. 51, 102886
- https://doi.org/10.1016/j.msard.2021.102886
Abstract
No abstract availableFunding Information
- Biogen Inc
This publication has 16 references indexed in Scilit:
- Risk of COVID-19 infection in MS and neuromyelitis optica spectrum disordersNeurology Neuroimmunology & Neuroinflammation, 2020
- Clinical Characteristics and Outcomes in Patients With Coronavirus Disease 2019 and Multiple SclerosisJAMA Neurology, 2020
- Evaluation of COVID-19 infection in patients with Neuromyelitis optica spectrum disorder (NMOSD): A report from IranMultiple Sclerosis and Related Disorders, 2020
- Treating multiple sclerosis and neuromyelitis optica spectrum disorder during the COVID-19 pandemicNeurology, 2020
- Mild COVID-19 infection despite chronic B cell depletion in a patient with aquaporin-4-positive neuromyelitis optica spectrum disorder.Multiple Sclerosis and Related Disorders, 2020
- An Italian programme for COVID-19 infection in multiple sclerosisThe Lancet Neurology, 2020
- The COVID-19 pandemic and the use of MS disease-modifying therapiesMultiple Sclerosis and Related Disorders, 2020
- Infection Risks Among Patients With Multiple Sclerosis Treated With Fingolimod, Natalizumab, Rituximab, and Injectable TherapiesJAMA Neurology, 2020
- Infections in Patients Receiving Multiple Sclerosis Disease-Modifying TherapiesCurrent Neurology and Neuroscience Reports, 2017
- Disease-modifying therapies and infectious risks in multiple sclerosisNature Reviews Neurology, 2016